New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
08:07 EDTGHDXGenomic Health announces positive results of Oncotype DX in colon cancer
Genomic Health announced results from three studies of the Oncotype DX Colon Cancer test at the 2013 Gastrointestinal Cancers Symposium, including new data demonstrating that Recurrence Score results changed treatment recommendations in 45% of the enrolled stage II colon cancer patients. Presentations also include positive findings from a second health economics analysis suggesting that use of the test may result in a significant reduction in direct medical costs and improve patient well-being.
News For GHDX From The Last 14 Days
Check below for free stories on GHDX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 9, 2014
08:05 EDTGHDXGenomic Health to present positive results from nine studies of Oncotype DX
Genomic Health announced that results from nine studies of Oncotype DX in prostate, breast and renal cancers will be presented at the European Society for Medical Oncology, or ESMO, 2014 Congress in Madrid, September 26 30. Included in the program is the first presentation of strongly positive results from an additional large independent clinical validation study of the Oncotype DX prostate cancer test, conducted in collaboration with the Center for Prostate Disease Research, Rockville. This new study demonstrates the test's ability to predict a rise in prostate-specific antigen, or PSA, following surgery and reconfirms Oncotype DX as a predictor of adverse pathology from the biopsy, as previously demonstrated in a published validation study performed by the University of California, San Francisco.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use